Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 20, Pages 5181
Publisher
MDPI AG
Online
2021-10-18
DOI
10.3390/cancers13205181
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Switching CAR-T cells on and off
- (2021) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
- (2021) Elise A. Chong et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinical pipeline for cancer cell therapies
- (2021) Samik Upadhaya et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
- (2020) Le Qin et al. Biomarker Research
- Immunotherapy for T-Cell ALL and T-Cell NHL
- (2020) John F. DiPersio et al. Clinical Lymphoma Myeloma & Leukemia
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
- (2020) Robert J. Cronk et al. Cancers
- First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
- (2019) Nancy L. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Novel and emerging therapies for B cell lymphoma
- (2019) Sabarish Ayyappan et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19
- (2019) Maria Ormhøj et al. CLINICAL CANCER RESEARCH
- KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
- (2019) Simone Ferrero et al. HAEMATOLOGICA
- CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
- (2019) Hong Qin et al. Science Translational Medicine
- Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
- (2019) Xiao Han et al. Journal of Hematology & Oncology
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
- (2018) Christos Georgiadis et al. MOLECULAR THERAPY
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
- (2014) Mehdi Hamadani et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma
- (2014) Shu Yang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- (2013) Sarah J. Nagle et al. AMERICAN JOURNAL OF HEMATOLOGY
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
- (2013) J. Radford et al. BLOOD
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
- (2013) H. Torikai et al. BLOOD
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Piecing together the family portrait of TCR-CD3 complexes
- (2012) Michael S. Kuhns et al. IMMUNOLOGICAL REVIEWS
- Non-Hodgkin lymphoma
- (2012) Kate R Shankland et al. LANCET
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
- (2008) Annina Herrmann et al. JOURNAL OF CLINICAL ONCOLOGY
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search